Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares MSCI India ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.7 (market cap $39.89B), while iShares MSCI India ETF trades at $48.93. The key difference: iShares MSCI India ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | INDA | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $55.29 |
52-Week Low | $278.09 | $45.42 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
INDA, the iShares MSCI India ETF, trades at $49.30 with a slight 0.57% daily gain amid a predominantly bearish technical outlook. The ETF faces mixed sentiment with India's strong 7.8% GDP growth (CNBC, 2026-06-05) contrasting with sectoral challenges in IT and clean energy. Technical indicators show neutral oscillators but bearish moving averages, with all support and resistance levels clustered around $49.
The outlook remains cautious due to macroeconomic risks from Middle East conflicts and domestic sector pressures. However, India's position as the fastest-growing large economy and analyst price targets suggesting upside potential (Seeking Alpha, 2026-06-03) offer long-term opportunities amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
